Mineralys Therapeutics, Inc. ( (MLYS) ) has released its Q4 earnings. Here is a breakdown of the information Mineralys Therapeutics, Inc. presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for hypertension, chronic kidney disease, obstructive sleep apnea, and other diseases related to dysregulated aldosterone.
In its recent earnings report, Mineralys Therapeutics announced financial results for the fourth quarter and full year of 2024, alongside several key clinical developments. The company is advancing its pivotal trials with expectations to release topline data from the Advance-HTN trial in March 2025 and the Launch-HTN Phase 3 trial by mid-2025.
Key financial highlights include a net loss of $177.8 million for the year, primarily driven by increased research and development expenses, which rose to $168.6 million due to the initiation of the lorundrostat pivotal program. Despite these expenses, Mineralys maintains $198.2 million in cash and investments, sufficient to fund operations through the first quarter of 2026.
The company is also progressing with its Explore-CKD and Explore-OSA Phase 2 trials, with the former having completed enrollment and the latter set to initiate in early 2025. These efforts highlight Mineralys’ strategic focus on expanding the potential therapeutic applications of lorundrostat.
Looking ahead, Mineralys Therapeutics remains optimistic about its clinical milestones and the potential impact of lorundrostat on treating high-risk patients with conditions affected by dysregulated aldosterone, setting the stage for significant developments in 2025.
